Is Biohaven Ltd. (BHVN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.8% / 30% | 36.9% / 30% | 0.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.8% / 33% | 36.9% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 5.9% / 33% | 79.0% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.8% / 33% | 36.9% / 33% | 0.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 5.9% / 33% | 79.0% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -310.8% | |
| Return on Assets (ROA) | -83.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$609M |
| Free Cash Flow | -$610M |
| Total Debt | $285M |
| Debt-to-Equity | 546.6 |
| Current Ratio | 3.2 |
| Total Assets | $451M |
Price & Trading
| Last Close | $8.92 |
| 50-Day MA | $11.03 |
| 200-Day MA | $12.84 |
| Avg Volume | 2.8M |
| Beta | 3.5 |
|
52-Week Range
$7.48
| |
About Biohaven Ltd. (BHVN)
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Biohaven Ltd. (BHVN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Biohaven Ltd. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Biohaven Ltd.'s debt ratio?
Biohaven Ltd.'s debt ratio is 2.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.9%.
What are Biohaven Ltd.'s key financial metrics?
Biohaven Ltd. has a market capitalization of $1.3B. Return on equity stands at -310.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.